Extracted from this filing and checked against the source text.
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.9
Gain Therapeutics, Inc. shareholders approved Ratification of selection of Ernst & Young AG as independent registered public accounting firm for fiscal year ending December 31, 2023 at the 2023-06-23 meeting.
- Proposal
- auditor ratification
- Outcome
- passed
- Meeting
- 2023-06-23
Exact text from the filing
Proposal 2 – Ratification of the Selection by the Audit Committee of the Board of Directors of Ernst & Young AG as the Independent Registered Public Accounting Firm of the Company for its Fiscal Year Ending December 31, 2023 The Company’s stockholders approved Proposal 2. The votes cast were as follows: For Against Abstain 7,927,104 4,642 11,513
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.9
Gain Therapeutics, Inc. shareholders approved Election of eight nominees for director to serve until 2024 Annual Meeting at the 2023-06-23 meeting.
- Proposal
- director election
- Outcome
- passed
- Meeting
- 2023-06-23
Exact text from the filing
Proposal 1 - Election of Directors The Company’s stockholders elected the eight persons listed below as directors, each to serve until the Company’s 2024 Annual Meeting of Stockholders and until their respective successors are duly elected and qualified. The votes cast were as follows: Nominees For Withheld Broker Non-Votes Matthias Alder 3,718,412 19,996 4,204,851 Dov Goldstein, M.D. 3,659,322 79,086 4,204,851 Hans Peter Hasler 3,491,745 246,663 4,204,851 Khalid Islam, Ph.D. 3,684,791 53,617 4,204,851 Gwen Melincoff 3,719,922 18,486 4,204,851 Claude Nicaise, M.D. 3,648,185 90,223 4,204,851 Eric I. Richman 3,711,215 27,193 4,204,851 Jeffrey Riley 3,716,202 22,206 4,204,851
View on SEC.gov